A comparison of multiple doses of fluticasone propionate and beclomethasone dipropionate in subjects with persistent asthma

Background: Inhaled corticosteroids are recommended for the treatment of pe rsistent asthma. Comparative clinical studies evaluating 2 or more doses of these agents are few. Objective: We sought to compare the efficacy and safety of 2 doses of fluti casone propionate (88 mu g twice daily and 220 mu g twice daily) with 2 dos es of beclomethasone dipropionate (168 mu g twice daily and 336 mu g twice daily) in subjects with persistent asthma, Methods: Three hundred ninety-nine subjects participated in this randomized , double-blind, parallel-group clinical trial. Eligible subjects were using daily inhaled corticosteroids and had an FEV1 of 45% to 80% of predicted v alue. Clinic visits, including spirometry; were conducted every 1 to 2 week s. Subjects recorded symptoms, use of albuterol, and peak expiratory Bows o n daily diary cards. Results: Fluticasone propionate treatment resulted in significantly (P less than or equal to .034) greater improvements in objective pulmonary functio n parameters than did beclomethasone dipropionate; treatment and significan tly greater reductions in daily albuterol use (P less than or equal to .010 ) and asthma symptoms (P less than or equal to .027). Both low-dose (88 mu g twice daily) and medium-dose (220 mu g twice daily) fluticasone propionat e significantly increased FEV1 compared with higher doses of beclomethasone dipropionate (P = .006), Low-dose and medium-dose fluticasone propionate i mproved FEV1 by 0.31 L (14%) and 0.36 L (15%), respectively, compared with improvements of 0.18 L (8%) and 0.21 L (9%) with low-dose and medium-dose b eclomethasone dipropionate. The adverse event profiles were similar for bot h medications. Conclusion: Fluticasone propionate provides greater asthma control at rough ly half the dose of beclomethasone dipropignate, with a comparable adverse event profile.